The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [11C] CURB

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 8, 2015, Pages 1237-1240

  Boileau, Isabelle ^a,b,c   Tyndale, Rachel F ^a,b   Williams, Belinda ^a   Mansouri, Esmaeil ^a   Westwood, Duncan J ^a,c   Le Foll, Bernard ^a,b,c   Rusjan, Pablo M ^a,b   Mizrahi, Romina ^a,b,c   De Luca, Vincenzo ^a,b,c   Zhou, Qian ^b   Wilson, Alan A ^a   Houle, Sylvain ^a   Kish, Stephen J ^a,b,c   Tong, Junchao ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

FAAH polymorphism (rs324420, C385A); fatty acid amide hydrolase; positron emission tomography; 11C CURB

Indexed keywords

6 HYDROXY [1,10 BIPHENYL] 3 YL CYCLOHEXYLCARBAMATE C 11; FATTY ACID AMIDASE; TRACER; UNCLASSIFIED DRUG; AMIDASE; FATTY-ACID AMIDE HYDROLASE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BRAIN; C385A GENE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; ALLELE; ANXIETY DISORDER; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED; RADIOGRAPHY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; AMIDOHYDROLASES; ANXIETY DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84938749459     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.119     Document Type: Article

References (15)

1. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A. Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 2013; 34: 637-644
2. Lopez-Moreno JA, Echeverry-Alzate V, Buhler KM. The genetic basis of the endocannabinoid system and drug addiction in humans. J Psychopharmacol 2012; 26: 133-143
3. Dincheva I, Drysdale AT, Hartley CA, Johnson DC, Jing D, King EC et al. FAAH genetic variation enhances fronto-Amygdala function in mouse and human. Nat Commun 2015; 6: 6395
4. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002; 99: 8394-8399
5. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 2004; 13: 2113-2119
6. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 2010; 5: e8792
7. Hariri AR, Gorka A, Hyde LW, Kimak M, Halder I, Ducci F et al. Divergent effects of genetic variation in endocannabinoid signaling on human threat- and rewardrelated brain function. Biol Psychiatry 2009; 66: 9-16
8. Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 660-666
9. Wilson AA, Garcia A, Parkes J, Houle S, Tong J, Vasdev N. [11C]CURB: evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography. Nucl Med Biol 2011; 38: 247-253
10. Rusjan PM, Wilson AA, Mizrahi R, Boileau I, Chavez SE, Lobaugh NJ et al. Mapping human brain fatty acid amide hydrolase activity with PET. J Cereb Blood Flow Metab 2013; 33: 407-414
11. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al. An automated method for the extraction of regional data from PET images. Psychiatry Res 2006; 147: 79-89
12. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002; 298: 1793-1796
13. Maccarrone M, Attina M, Bari M, Cartoni A, Ledent C, Finazzi-Agro A. Anandamide degradation and N-Acylethanolamines level in wild-Type and CB1 cannabinoid receptor knockout mice of different ages. J Neurochem 2001; 78: 339-348
14. Bishay P, Haussler A, Lim HY, Oertel B, Galve-Roperh I, Ferreiros N et al. Anandamide deficiency and heightened neuropathic pain in aged mice. Neuropharmacology 2013; 71: 204-215
15. Pascual AC, Martin-Moreno AM, Giusto NM, de Ceballos ML, Pasquare SJ. Normal aging in rats and pathological aging in human Alzheimer's disease decrease FAAH activity: modulation by cannabinoid agonists. Exp Gerontol 2014; 60: 92-99